文献速递眼底病与葡萄膜炎

靶向PDGF-C的抑制性核酸适配体克服抗VEGF耐药并减少脉络膜新生血管与纤维化

An Inhibitory Aptamer Against PDGF-C Overcomes Anti-VEGF Refractoriness and Reduces Choroidal Neovascularization and Fibrosis.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

本研究鉴定了一种靶向血小板衍生生长因子C(PDGF-C)的DNA核酸适配体α-PC,并评估其抑制脉络膜新生血管(CNV)和纤维化的治疗潜力。该适配体特异性结合PDGF-C并阻断其与PDGFRα的相互作用,抑制下游PDGFRα、Akt和ERK激活,在激光诱导CNV小鼠模型中显著减少新生血管和纤维化,且在抗VEGF耐药的老年小鼠中仍保留抑制CNV的疗效。

要点

  • α-PC适配体特异性结合PDGF-C并阻断PDGF-C/PDGFRα相互作用。
  • α-PC适配体抑制PDGFRα、Akt和ERK激活及PDGF-C诱导的增殖和迁移。
  • 在抗VEGF耐药的老年CNV小鼠中,α-PC适配体仍能抑制CNV。

核心结论

  • α-PC适配体是治疗新生血管性疾病的有前景药物,尤其适用于抗VEGF治疗耐药的患者。

研究设计与样本

  • 通过指数富集配体系统进化技术鉴定靶向PDGF-C的DNA适配体α-PC。
  • 采用表面等离子共振评估α-PC与PDGF-C结合及阻断PDGF-C/PDGFRα相互作用。
  • 在成纤维细胞和HUVSMC中检测α-PC对PDGF-C诱导增殖、迁移及PDGFRα、Akt、ERK信号的影响。
  • 在激光诱导CNV小鼠模型(包括抗VEGF耐药的老年小鼠)中评估体内疗效。

主要发现

  • α-PC适配体特异性结合PDGF-C并有效阻断其与PDGFRα结合。
  • α-PC适配体显著抑制PDGFRα、Akt和ERK激活,并抑制PDGF-C诱导的成纤维细胞和HUVSMC增殖与迁移。
  • 在激光诱导CNV小鼠模型中,α-PC适配体显著减少新生血管和纤维化。
  • 在抗VEGF耐药的老年小鼠中,α-PC适配体仍保留抑制CNV的疗效,而抗VEGF治疗无效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Wet age-related macular degeneration is a leading cause of irreversible vision loss, primarily due to choroidal neovascularization (CNV) and subsequent fibrosis. Although current anti-vascular endothelial growth factor A (anti-VEGF) therapies offer significant benefits, many patients exhibit limited or no response and develop drug resistance over time, necessitating the exploration of complementary or alternative therapeutics. This study aimed to identify and characterize a platelet-derived growth factor-C (PDGF-C)-targeting DNA aptamer and to evaluate its therapeutic potential for suppressing CNV and fibrosis, including in an anti-VEGF-refractory setting. METHODS: A DNA aptamer against PDGF-C (α-PC aptamer) was identified using systematic evolution of ligands by exponential enrichment. Its binding to PDGF-C and inhibition of PDGF-C/platelet-derived growth factor receptor alpha (PDGFRα) interaction were assessed using surface plasmon resonance. The effects of the α-PC aptamer on PDGF-C-induced proliferation, migration, and PDGFRα, Akt, and extracellular-regulated kinase (ERK) signaling were examined in fibroblasts and human umbilical vein smooth muscle cells (HUVSMCs). In vivo efficacy was evaluated in a laser-induced CNV mouse model, including anti-VEGF refractory aged mice. RESULTS: The α-PC aptamer specifically bound to PDGF-C and effectively blocked its binding to PDGFRα. The α-PC aptamer significantly inhibited PDGFRα, Akt, and ERK activation and suppressed PDGF-C-induced proliferation and migration of both fibroblasts and HUVSMCs. Importantly, in a laser-induced CNV mouse model, the α-PC aptamer markedly reduced neovascularization and fibrosis; it particularly retained efficacy in suppressing CNV in anti-VEGF refractory aged mice, where anti-VEGF treatment failed to do so. CONCLUSIONS: These findings suggest that the α-PC aptamer represents a promising therapeutic agent for treating neovascular diseases, especially in patients refractory to anti-VEGF treatment.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Chen R, Lu W, Zhu J, et al. An Inhibitory Aptamer Against PDGF-C Overcomes Anti-VEGF Refractoriness and Reduces Choroidal Neovascularization and Fibrosis. Invest Ophthalmol Vis Sci. 2026. PMID: 42138517. doi:10.1167/iovs.67.5.36

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。